Key clinical point: A highly potent and selective topical phosphodiesterase-4 inhibitor in a cream formulation rapidly improves psoriasis without a favorable side effect profile.
Major finding: A week 8 Investigator Global Assessment of 0 or 1 plus at least a 2-grade improvement from baseline occurred in 32% of the high-dose roflumilast group, 25% of those on the 0.15% formulation, and 10% of controls.
Study details: This 12-week, double-blind, multicenter, randomized trial included 331 psoriasis patients.
Disclosures: The phase 2b study was funded by Arcutis Biotherapeutics. The presenter reported receiving research funding from and serving as a consultant to that company and numerous others.
Lebwohl M. AAD 2020.